Beulah Ji

2.6k total citations · 1 hit paper
31 papers, 1.6k citations indexed

About

Beulah Ji is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Beulah Ji has authored 31 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Rheumatology, 15 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Immunology. Recurrent topics in Beulah Ji's work include Systemic Lupus Erythematosus Research (26 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and T-cell and B-cell Immunology (9 papers). Beulah Ji is often cited by papers focused on Systemic Lupus Erythematosus Research (26 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and T-cell and B-cell Immunology (9 papers). Beulah Ji collaborates with scholars based in United States, United Kingdom and China. Beulah Ji's co-authors include David A. Roth, C. Kleoudis, Richard Furie, Michelle Petri, Yulia Green, Xueqing Yu, Ronald van Vollenhoven, Brad H. Rovin, Ana Malvar and Y K Onno Teng and has published in prestigious journals such as New England Journal of Medicine, Hepatology and Kidney International.

In The Last Decade

Beulah Ji

31 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

2020 549 citations Richard Furie, Brad H. Rovin et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beulah Ji United States	14	1.3k	880	619	311	210	31	1.6k
Ana Malvar Argentina	16	1.3k 1.0×	753 0.9×	397 0.6×	713 2.3×	266 1.3×	45	1.6k
Juanita Romero‐Díaz Mexico	17	1.0k 0.8×	639 0.7×	272 0.4×	199 0.6×	109 0.5×	50	1.3k
Renato Guzmán United States	5	1.4k 1.1×	1.1k 1.3×	767 1.2×	174 0.6×	90 0.4×	10	1.8k
Paula Alba Argentina	9	1.2k 1.0×	672 0.8×	273 0.4×	245 0.8×	134 0.6×	34	1.4k
Dana Tegzová Czechia	15	1.7k 1.3×	1.0k 1.2×	657 1.1×	166 0.5×	123 0.6×	22	2.1k
Juan Carlos Mejía United States	10	909 0.7×	514 0.6×	189 0.3×	173 0.6×	114 0.5×	27	1.3k
Neil Solomons United States	11	1.9k 1.4×	646 0.7×	373 0.6×	1.1k 3.5×	610 2.9×	23	2.1k
Anna Berglind Sweden	9	983 0.8×	756 0.9×	427 0.7×	59 0.2×	77 0.4×	12	1.4k
M. L. Snaith United Kingdom	12	969 0.7×	571 0.6×	331 0.5×	122 0.4×	69 0.3×	14	1.2k
Tom J. G. Swaak Netherlands	20	821 0.6×	451 0.5×	338 0.5×	222 0.7×	100 0.5×	26	1.1k

Countries citing papers authored by Beulah Ji

Since Specialization

Citations

This map shows the geographic impact of Beulah Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beulah Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beulah Ji more than expected).

Fields of papers citing papers by Beulah Ji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beulah Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beulah Ji. The network helps show where Beulah Ji may publish in the future.

Co-authorship network of co-authors of Beulah Ji

This figure shows the co-authorship network connecting the top 25 collaborators of Beulah Ji. A scholar is included among the top collaborators of Beulah Ji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beulah Ji. Beulah Ji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

D’Cruz, David, et al.. (2023). Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data. Lupus Science & Medicine. 10(1). e000830–e000830. 3 indexed citations

Bae, Sang‐Cheol, Damon Bass, Myron Chu, et al.. (2022). The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. Arthritis Research & Therapy. 24(1). 46–46. 8 indexed citations

Yu, Xueqing, Nan Chen, Junmin Xue, et al.. (2022). Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population. American Journal of Kidney Diseases. 81(3). 294–306.e1. 28 indexed citations

Brunner, Hermine I., Carlos Abud‐Mendoza, Masaaki Mori, et al.. (2021). Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 7(3). e001747–e001747. 19 indexed citations

Tanaka, Yoshiya, Sang‐Cheol Bae, Damon Bass, et al.. (2021). Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. 7(2). e001629–e001629. 18 indexed citations

Liang, Zhenyu, Nanshan Zhong, Rongchang Chen, et al.. (2021). Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale. ERJ Open Research. 7(3). 201–2021. 6 indexed citations

Rovin, Brad H., Richard Furie, Y K Onno Teng, et al.. (2021). A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney International. 101(2). 403–413. 112 indexed citations

D’Cruz, David, et al.. (2021). POS0696 SAFETY AND EFFICACY OF BELIMUMAB IN OLDER ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF AN INTEGRATED ANALYSIS. Annals of the Rheumatic Diseases. 80. 596–596. 2 indexed citations

Ginzler, Ellen M., David D’Cruz, Richard Furie, et al.. (2021). Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 74(1). 112–123. 72 indexed citations

10.

Henderson, Robert B., Angela R. Jones-Leone, Shaun Flint, et al.. (2020). The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. Arthritis Research & Therapy. 22(1). 102–102. 28 indexed citations

11.

Ji, Beulah, et al.. (2020). Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. Clinical Pharmacology in Drug Development. 10(6). 622–633. 13 indexed citations

12.

Furie, Richard, Brad H. Rovin, Frédéric Houssiau, et al.. (2020). Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine. 383(12). 1117–1128. 549 indexed citations breakdown →

13.

Wallace, Daniel J., Ellen M. Ginzler, Joan T. Merrill, et al.. (2019). Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 71(7). 1125–1134. 84 indexed citations

14.

Tanaka, Yoshiya, et al.. (2019). Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Modern Rheumatology. 30(2). 313–320. 12 indexed citations

15.

Vollenhoven, Ronald van, Sandra Navarra, Roger A. Levy, et al.. (2019). Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Lara D. Veeken. 59(2). 281–291. 64 indexed citations

16.

Davidson, Julie, Qinggong Fu, Beulah Ji, et al.. (2018). Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. The Journal of Rheumatology. 45(5). 671–677. 46 indexed citations

17.

Jayne, David, Daniël Blockmans, Raashid Luqmani, et al.. (2018). AB0692 Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers. Annals of the Rheumatic Diseases. 77. 1488–1488. 1 indexed citations

18.

Jayne, David, Daniël Blockmans, Raashid Luqmani, et al.. (2017). Efficacy and Safety of Belimumab in Combination with Azathioprine for Remission Maintenance in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: A Multicenter Randomized, Placebo-Controlled Study. Lirias (KU Leuven). 69. 3 indexed citations

19.

Vollenhoven, Ronald van, Michelle Petri, Ricard Cervera, et al.. (2012). Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Annals of the Rheumatic Diseases. 71(8). 1343–1349. 294 indexed citations

20.

Zeng, Minde, Yimin Mao, Hao Wang, et al.. (2006). A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 44(1). 108–116. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact